BDX 10-K Annual Reports

Becton, Dickinson and Company (BDX) reported revenues of $21.84 billion for the fiscal year ending September 30, 2025, an increase of 8.2% year-over-year. This growth was primarily driven by the acquisition of Edwards Lifesciences' Critical Care product group, now known as BD Advanced Patient Monitoring, which contributed 4.8% to the revenue increase. The company continues to navigate a dynamic market, focusing on its strategic objectives of growth, simplification, and empowerment. BD also announced its definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation in a Reverse Morris Trust transaction, expected to close by the end of the first quarter of calendar year 2026, which will result in BD shareholders owning approximately 39.2% of the combined entity. Key operational highlights include continued growth across its Medical and Interventional segments, although the Life Sciences segment experienced a slight revenue decline. The company faces ongoing challenges related to supply chain disruptions, inflation, and regulatory complexities, particularly concerning the FDA's consent decree for its Alaris infusion pump business and a recent warning letter for its dispensing quality management system. BD is actively managing these challenges and investing in innovation and operational efficiency to drive future growth and shareholder value.

Becton, Dickinson and Company (BDX) reported revenues of $20.178 billion for the fiscal year ended September 29, 2024, representing a 4.2% increase year-over-year. This growth was driven by strong performance across its Medical, Life Sciences, and Interventional segments, notably boosted by the recent acquisition of Edwards Lifesciences' Critical Care product group. The company highlighted strategic objectives centered on growth, simplification, and empowerment, with a focus on innovation in smart devices, robotics, and AI. While facing some headwinds from market dynamics in China and inflationary pressures on labor and materials, BD demonstrated resilience with robust operating income and significant cash flow from continuing operations. The company continued to return value to shareholders through dividends and share repurchases. BD is actively managing various risks, including supply chain disruptions, regulatory scrutiny (particularly with its Alaris infusion pump business and a recent FDA warning letter for dispensing products), and cybersecurity threats. The company's proactive approach to risk management and commitment to innovation position it for continued development in the global medical technology market.

Becton, Dickinson and Company (BDX) reported fiscal year 2023 revenues of $19.372 billion, a 2.7% increase over the prior year, driven by volume growth and pricing, although partially offset by a decline in COVID-19-related testing sales and foreign currency translation impacts. The company's strategic objectives for value creation are centered around growing its portfolio, simplifying operations, and empowering its workforce. Despite inflationary pressures on raw materials, labor, and energy, BD maintained strong operating cash flows and returned value to shareholders through dividends. Key areas of focus include innovation in smart devices, expanding global access to medical technologies, and enhancing operational efficiencies. However, the company continues to navigate challenges, including the ongoing remediation efforts related to its Alaris™ infusion pumps, which significantly impacted the Medical segment's operating income, and the broader impacts of global macroeconomic conditions and geopolitical factors. BDx operates across three main segments: Medical, Life Sciences, and Interventional, each contributing to its diverse product offerings. The company remains committed to investing in research and development to maintain its competitive edge in the dynamic medical technology landscape.

Becton, Dickinson and Company (BDX) reported revenues of $18.87 billion for the fiscal year ended September 30, 2022, a slight decrease of 1.4% compared to the prior year. This decline was primarily driven by a significant drop in COVID-19 related diagnostic test sales, which decreased from $1.956 billion in FY2021 to $511 million in FY2022. Excluding the impact of COVID-19 testing, the company experienced a volume increase of 6.2%, indicating growth in its core product lines across all three segments: Medical, Life Sciences, and Interventional. The company completed the acquisition of Parata Systems for $1.548 billion in July 2022, strengthening its presence in pharmacy automation. Concurrently, BD completed the spin-off of its Diabetes Care business, Embecta Corp., on April 1, 2022. The company continues to focus on strategic objectives of growth, simplification, and empowerment, including investments in R&D and portfolio expansion. Despite inflationary pressures and supply chain challenges, BD maintained a strong financial position, with $2.471 billion in cash flows from continuing operations and returning value to shareholders through dividends and share repurchases.

Becton, Dickinson and Company (BDX) reported robust revenue growth of 18.3% in fiscal year 2021, reaching $20.25 billion, driven by a significant recovery in medical procedures and strong demand across its Medical, Life Sciences, and Interventional segments. The Life Sciences segment, in particular, saw a substantial boost from COVID-19 diagnostic testing solutions. Despite global economic uncertainties and supply chain challenges exacerbated by the pandemic, BD demonstrated strong operating performance and cash flow generation, with operating income reaching $2.8 billion. The company continues to invest in R&D and strategic initiatives aimed at innovation and efficiency, as outlined in its BD 2025 strategy. BD also reaffirmed its commitment to shareholder returns through dividends and share repurchases. Looking ahead, BD announced its intention to spin off its Diabetes Care business into a separate publicly traded company, a strategic move aimed at allowing both entities to focus on their respective growth strategies and capital allocation. The company also navigated various risk factors, including the ongoing impact of the COVID-19 pandemic, supply chain disruptions, and ongoing regulatory considerations, while maintaining effective internal controls. The company's financial position remains strong, supported by healthy cash flows and access to credit facilities.

Becton, Dickinson and Company (BDX) reported revenues of $17.12 billion for the fiscal year ended September 29, 2020, a slight decrease of 1.0% from the prior year, primarily impacted by the COVID-19 pandemic, which reduced overall volume by an estimated 3.3%. Despite the pandemic's challenges, the Life Sciences segment saw growth driven by COVID-19 diagnostic testing. The company's financial position remained strong, with significant cash flows from operations, and it continued to return value to shareholders through dividends. However, BD faces ongoing risks including the unpredictable impact of the COVID-19 pandemic, competition, foreign currency fluctuations, and regulatory challenges, notably an amended consent decree with the FDA for its Alaris infusion pumps. The company's strategic objectives focus on growing its product portfolio, simplifying operations, and empowering its workforce. Significant investments in research and development are ongoing to drive innovation. BD also addressed its capital structure, managing debt and completing equity offerings to enhance financial flexibility. Investors should monitor the company's progress in navigating the pandemic's effects and its ongoing remediation efforts for the Alaris system.

Becton, Dickinson and Company (BDX) reported fiscal year 2019 revenues of $17.29 billion, an increase of 8.2% over the prior year. This growth was primarily driven by the inclusion of results from the C.R. Bard acquisition, which closed in late 2017, and organic volume growth across its three key segments: Medical, Life Sciences, and Interventional. The company continues to focus on its core strategies of innovation, geographic expansion in emerging markets, and improving operational effectiveness. BDX is actively managing its balance sheet and debt obligations following the Bard acquisition, with total debt at $19.39 billion. The company generated strong operating cash flow of $3.33 billion, supporting its dividend payments and investments in research and development. Management highlighted continued investment in new products and platforms to drive future revenue and profit growth. Investors should note the ongoing management of regulatory matters, including a consent decree related to infusion pumps and a warning letter for a Preanalytical Systems facility, as well as significant legal reserves related to product liability claims, particularly for hernia and women's health products.

Becton, Dickinson and Company (BDX) reported a significant increase in revenues for the fiscal year ended September 30, 2018, largely driven by the transformative acquisition of C.R. Bard, Inc. (Bard) completed in December 2017. This strategic move has positioned BD as a more comprehensive medical technology provider across its three key segments: Medical, Life Sciences, and Interventional. While the integration of Bard presents opportunities for growth and synergies, it also introduces integration costs and increased debt levels, which management is actively working to manage. Financially, the company experienced substantial revenue growth, fueled by the Bard acquisition and organic volume growth across its segments, particularly in Medication Delivery Solutions and Diagnostic Systems. However, diluted earnings per share were significantly impacted by "specified items," including substantial integration and acquisition-related costs, and a large one-time tax expense due to the U.S. Tax Cuts and Jobs Act. Investors should closely monitor the ongoing integration process, management's ability to realize cost savings, and the impact of regulatory matters, including FDA warning letters, on future performance.

Becton, Dickinson and Company (BDX) filed its 2017 10-K, reporting on its fiscal year ending September 29, 2017. The company, a global medical technology firm, operates through two main segments: BD Medical and BD Life Sciences. A significant development during the year was the announcement of the definitive agreement to acquire C. R. Bard, Inc. for approximately $24 billion, a transaction expected to close in the fourth quarter of 2017. This acquisition aims to create a more differentiated medical technology company. Financially, revenues for fiscal year 2017 were $12.093 billion, a decrease of 3.1% from the prior year, primarily due to the divestiture of the Respiratory Solutions business. Despite the revenue dip, the company continued to invest in research and development ($774 million) and returned value to shareholders through dividends and share repurchases. The company's financial position remains strong, with significant cash on hand, bolstered by equity and debt issuances to support the upcoming Bard acquisition. Management expressed confidence in its ability to fund operations and strategic initiatives, while acknowledging risks related to the integration of acquisitions and global economic conditions.

Becton, Dickinson and Company (BDX) reported robust revenue growth in fiscal year 2016, driven significantly by the full-year inclusion of its CareFusion acquisition. Total revenues reached $12.48 billion, a 21.4% increase over the prior year. The company operates through two main segments: BD Medical and BD Life Sciences, both contributing to the overall revenue growth, with Medical showing a substantial 34.0% increase year-over-year, largely due to the CareFusion integration. The company continued its strategic focus on increasing revenue growth through core products, R&D investment, emerging market expansion, and operational efficiency. Despite increased debt related to the CareFusion acquisition, BD maintained its investment-grade credit rating and generated strong operating cash flows, highlighting its financial stability and commitment to shareholder returns through dividends.

Becton, Dickinson and Company (BDX) reported significant growth in fiscal year 2015, largely driven by the transformative acquisition of CareFusion in March 2015. This acquisition positioned BD as a leader in medication management and patient safety solutions. Despite a substantial increase in debt to fund the CareFusion deal, the company demonstrated revenue growth across both its Medical and Life Sciences segments, with the Medical segment showing particular strength due to the inclusion of CareFusion's operations. While the company faced increased interest expenses and integration costs related to the acquisition, its strategic focus on innovation, emerging markets, and operational efficiency remains. Investors should note the impact of acquisition-related costs and purchase accounting adjustments on the current year's profitability, which obscured the underlying operational performance. The company's commitment to returning shareholder value through dividends was maintained, though share repurchases were suspended to manage debt levels post-acquisition. Overall, the report signals a strategic shift with the CareFusion integration being the primary focus, aiming for long-term growth and market leadership.

Becton Dickinson & Co. (BDX) reported strong financial performance in its fiscal year 2014, with total revenues reaching $8.446 billion, a 4.9% increase over the prior year, driven by growth across its Medical and Biosciences segments, particularly in emerging markets and sales of safety-engineered products. The company's operational efficiency improved, with a gross profit margin of 50.9%. A significant development during the year was the announcement of a definitive agreement to acquire CareFusion Corporation for approximately $12.2 billion, a strategic move expected to create a leader in medication management and patient safety solutions, anticipated to close in the first half of calendar year 2015. BD demonstrated solid cash flow from operations, totaling $1.75 billion, which supported its dividend payments and share repurchases, though the latter was suspended in light of the CareFusion acquisition. The company navigated a complex regulatory and economic landscape, including the impact of the Patient Protection and Affordable Care Act's medical device excise tax. Key risks identified include global economic conditions, foreign currency fluctuations, and competitive pressures within the medical technology market. Management expressed confidence in the company's financial position and ability to access capital to fund its strategic objectives, including the significant CareFusion acquisition.

Becton Dickinson & Co. (BDX) reported a solid fiscal year 2013, with revenues reaching $8.1 billion, a 4.5% increase driven by volume growth and strategic acquisitions. The company operates across three key segments: Medical, Diagnostics, and Biosciences, all contributing to revenue growth, albeit with some regional variations and challenges, particularly in the U.S. Diagnostics segment due to weaker demand in its Women's Health and Cancer platform. BD continued its commitment to innovation and growth through targeted acquisitions like Safety Syringes, Inc. and Cato Software Solutions, and strategic divestitures such as the sale of its Discovery Labware unit. The company also maintained a strong focus on returning value to shareholders through dividends and share repurchases, alongside strategic investments in emerging markets and R&D. Despite facing headwinds from global economic conditions, healthcare reform, and a significant legal settlement charge in the fourth quarter, BD demonstrated resilience and a commitment to its strategic objectives.

Becton, Dickinson and Company (BDX) reported its 2012 fiscal year-end results, showcasing a global medical technology company with diversified operations across BD Medical, BD Diagnostics, and BD Biosciences segments. Despite a challenging global economic environment impacting healthcare utilization and pricing pressures, especially in its Biosciences segment, BD demonstrated revenue growth driven by new product launches and strategic acquisitions, including KIESTRA Lab Automation and Sirigen Group. The company continues to invest in research and development and emerging markets, aligning with its strategy to enhance shareholder value through innovation and operational efficiency. Financially, BD reported revenues of $7.7 billion, a 1.6% increase year-over-year, with solid growth in its Medical and Diagnostics segments. The company maintained a strong financial position with $2.2 billion in cash and equivalents. BD also actively returned capital to shareholders through share repurchases and dividends. Key risks identified include global economic conditions, foreign currency fluctuations, changes in healthcare reimbursement, and the impact of U.S. healthcare reform, notably the impending medical device excise tax. The company is also navigating several significant legal proceedings, including antitrust litigation, which could materially affect its financial results.

Becton Dickinson & Co. (BDX) reported strong financial performance for the fiscal year ending September 30, 2011. The company's revenues increased by 6% to $7.8 billion, driven by volume growth and favorable foreign currency translation, despite challenging economic conditions and a slight decrease in pricing. BD successfully integrated two key acquisitions: Accuri Cytometers, Inc. and Carmel Pharma Inc., strengthening its offerings in the life sciences and medical devices sectors, respectively. The company also continued its commitment to shareholder returns through significant share repurchases and dividend payments, while maintaining a strong balance sheet and cash flow from operations.

Becton, Dickinson and Company (BDX) reported revenues of $7.37 billion for the fiscal year ended September 29, 2010, marking a 5.5% increase from the prior year, driven primarily by solid revenue growth in the Medical Segment. The company's strategic focus remains on increasing revenue growth through core product enhancement, investing in research and development for innovative products, expanding presence in emerging markets, improving operational efficiency, and driving shareholder returns. BD reported operating income of $1.7 billion, with a strong cash flow from operations totaling $1.7 billion, demonstrating financial health. The company also returned value to shareholders through share repurchases and dividends, while maintaining a solid investment-grade credit rating. Key areas of focus for BD include enabling safer drug delivery, improving clinical outcomes through advanced diagnostics, providing research tools, and enhancing disease management in areas like diabetes and infection control. The company is navigating a complex market with evolving regulatory environments and increased competition, but remains committed to its growth strategies. Despite some legal proceedings and the impact of healthcare reform legislation, BDX's financial position appears robust, supported by diversified revenue streams and a strong operational foundation.

This amended 10-K filing for Becton Dickinson & Co. (BDX) as of September 29, 2009, primarily serves to provide accompanying certifications and exhibits related to the company's financial reporting. While it doesn't contain the full financial statements or management's discussion and analysis, the inclusion of CEO and CFO certifications under Rule 13a-14(a) and Section 1350 of U.S. Code signals the company's adherence to Sarbanes-Oxley Act requirements for the period. Investors should look to the original 10-K filing for detailed financial performance, operational strategies, and risk factors. For investors, the key takeaway from this amendment is the confirmation of compliance with internal control and disclosure procedures. The certifications attest to the accuracy and fairness of the financial reporting and the effectiveness of disclosure controls and procedures. The signature by the Vice President, Corporate Secretary and Public Policy indicates the formal submission and certification of the report on behalf of the company.

This filing is an amendment to Becton, Dickinson and Company's (BDX) Form 10-K for the fiscal year ended September 30, 2009. The amendment's sole purpose is to provide the "Valuation and Qualifying Accounts" (Schedule II) in interactive data format, which was inadvertently omitted from the original filing. For investors, this means the core financial performance and strategic information remain as detailed in the original 10-K. The company, a large accelerated filer, had a significant market capitalization of approximately $16 billion as of March 31, 2009, indicating its substantial size and established market presence. This amendment does not introduce new financial data or strategic changes but rather addresses a technical filing requirement.

Becton Dickinson & Co. (BDX) filed its 2009 10-K report on November 24, 2009, covering the fiscal year ended September 29, 2009. This filing provides a comprehensive overview of the company's business, financial performance, and strategic outlook. Investors can gain insights into the company's operations across its key segments, which typically include medical, diagnostic, and surgical products, by reviewing the "Business" section. The "Management's Discussion and Analysis of Financial Condition and Results of Operations" is crucial for understanding the drivers of revenue and profitability, as well as the company's liquidity and capital resources.

Becton Dickinson and Company (BDX) filed its 2008 10-K report, detailing its operations as a global medical technology company. The company is structured into three key segments: BD Medical, BD Diagnostics, and BD Biosciences, offering a wide array of products and devices for healthcare institutions, life science researchers, and clinical laboratories. The report highlights BD's commitment to innovation through significant investments in research and development, which are crucial for maintaining its competitive edge in a rapidly evolving medical technology landscape. BD's business is characterized by its diverse product portfolio and global presence, with substantial operations outside the U.S. The company emphasizes safety-engineered devices and diagnostic solutions, particularly in areas like infectious disease testing and cell analysis. However, BD also faces considerable risks, including the impact of current economic conditions, foreign currency fluctuations, intense competition, regulatory scrutiny, and ongoing legal proceedings, particularly antitrust litigation. Investors should note the company's efforts to mitigate these risks through strategic initiatives, product development, and operational efficiency.

This filing is an amendment (10-K/A) to Becton Dickinson and Company's (BDX) Annual Report on Form 10-K for the fiscal year ended September 30, 2007. The primary purpose of this amendment is to provide corrected certifications from the Chief Executive Officer and Chief Financial Officer, as required by SEC Rule 13a-14(a), which were inadvertently omitted in the original filing. Additionally, certifications required by Section 1350 of Chapter 63 of Title 18 of the U.S. Code are also included. Investors should note that this filing does not contain new financial performance data or business updates, but rather addresses procedural compliance with SEC regulations regarding executive certifications.

Becton, Dickinson and Company (BDX) reported its fiscal year results for the period ending September 30, 2007. The company operates across three global segments: BD Medical, BD Diagnostics, and BD Biosciences, offering a diverse range of medical supplies, devices, and diagnostic products. Key strategic developments in the fiscal year included the acquisitions of TriPath Imaging, Inc. and Plasso Technology, Ltd., aimed at strengthening BD's position in cancer diagnostics and advanced research tools, respectively. BD highlighted its ongoing commitment to innovation through substantial research and development investments. The company's extensive global manufacturing and distribution network supports its worldwide sales. Investors should note the competitive landscape and potential impacts of regulatory changes and third-party reimbursement policies on the company's performance. BD also faces ongoing litigation, which, while not currently assessed as material individually or in aggregate, remains a factor to monitor.

Becton, Dickinson and Company (BDX) reported its fiscal year ended September 30, 2006, highlighting its position as a leading medical technology company. The company operates across three primary segments: Medical, Diagnostics, and Biosciences, offering a diverse range of products and solutions for healthcare institutions, life science researchers, and clinical laboratories worldwide. BDX has strategically focused on growth through both internal development and acquisitions. Notable strategic moves in the reported period include the acquisition of GeneOhm Sciences, Inc., expanding its presence in healthcare-associated infection diagnostics, and the announced agreement to acquire TriPath Imaging, strengthening its cancer diagnostic offerings. The company also announced its exit from the blood glucose monitoring market, signaling a reallocation of resources. With a significant international presence, BDX navigates global economic conditions and currency fluctuations, while also addressing regulatory landscapes and competitive pressures inherent in the medical technology sector.

Becton, Dickinson and Company (BDX) presents its 2005 10-K report, detailing its operations as a global medical technology company. The company is structured into three core segments: BD Medical, BD Diagnostics, and BD Biosciences, offering a wide array of products for healthcare institutions, life science researchers, and clinical laboratories. BDX highlights its commitment to innovation and its diversified product portfolio, which mitigates risks associated with specific market shifts or regulatory changes. The company's global presence, with manufacturing and sales operations in numerous countries, contributes to its broad market reach. Investors should note the ongoing litigation, including product liability and antitrust cases, though the company believes it has strong defenses and that potential liabilities are largely covered by insurance. The report also mentions a potential impact from a new inhaled insulin form on its insulin device sales, which BD aims to mitigate through product strengths and market dynamics.

Becton, Dickinson and Company (BDX) filed its annual report for the fiscal year ended September 30, 2004. The company operates as a global medical technology firm across three primary segments: Medical, Diagnostics, and Biosciences. BD Medical focuses on devices for medication delivery, diabetes care, and surgical products. BD Diagnostics offers solutions for specimen collection and analysis, particularly in microbiology and infectious disease testing. BD Biosciences provides research and clinical tools for cell analysis, crucial for drug discovery and disease management. Key developments during the year included the acquisition of Atto Bioscience, Inc. to bolster the BD Biosciences segment, and the decision to divest the Clontech unit, which will be reported as discontinued operations. The company highlighted its commitment to research and development, investing approximately $236 million in fiscal year 2004. BDX also addressed ongoing litigation, including product liability cases related to latex gloves and needlestick injuries, as well as a significant settlement with Retractable Technologies, Inc. for $100 million. The company reported strong market presence and a diverse product portfolio, while acknowledging competitive pressures and regulatory oversight inherent in the medical technology sector.

Becton Dickinson and Company (BDX) filed its annual report on Form 10-K for the fiscal year ended September 30, 2003. The report provides a comprehensive overview of the company's business segments, operations, and financial condition. BDX operates as a global medical technology company with three primary segments: Medical, Diagnostics, and Biosciences. The Medical segment focuses on products like syringes, needles, and diabetes care devices. The Diagnostics segment offers microbiology products, specimen management systems, and diagnostic test kits. The Biosciences segment provides life science research tools, including flow cytometry systems and molecular biology products. The company emphasizes its commitment to research and development, with significant investments made over the past three fiscal years to drive product innovation and maintain a competitive edge in the dynamic medical technology market. BDX also highlights its global presence, with manufacturing and sales operations spanning numerous countries. While the company is subject to various risks and uncertainties inherent in the healthcare industry, including competition, regulatory changes, and economic factors, it maintains a strong focus on compliance and risk management.

Becton Dickinson & Co. (BDX) filed its 2002 10-K report on December 19, 2002, detailing its operations for the fiscal year ended September 30, 2002. The company operates as a global medical technology firm across three main segments: Medical Systems, Clinical Laboratory Solutions, and Biosciences. These segments provide a wide array of products and services, including injection devices, diabetes care products, diagnostic systems, and life science research tools. BD emphasizes its commitment to innovation and market leadership, supported by significant investments in research and development, which amounted to approximately $220 million in fiscal year 2002. BD's global presence is substantial, with manufacturing and sales operations spanning numerous countries. The company acknowledges the risks associated with international operations, including economic fluctuations and currency exchange rates. The report also highlights the competitive landscape, where BD competes with specialized companies and larger entities with greater financial resources. Key to its strategy is the maintenance of intellectual property and ongoing product innovation. The company also disclosed its position on significant legal proceedings, including product liability claims related to latex gloves and needlestick injuries, as well as an antitrust lawsuit. While management believes these matters will not have a material adverse effect, it acknowledges potential impacts on financial results and cash flows.

Becton Dickinson & Co. (BDX) filed its 2001 10-K on December 20, 2001, for the fiscal year ended September 30, 2001. The company operates in three global segments: Medical Systems, Clinical Laboratory Solutions, and Biosciences. BDX is a leading global manufacturer and seller of medical supplies, devices, laboratory equipment, and diagnostic products. The filing details BDX's business operations, competitive landscape, and legal proceedings. BDX's extensive global presence, with manufacturing and sales operations in numerous countries, is a key aspect of its business. The company emphasizes its commitment to research and development, investing $212 million in fiscal year 2001 to maintain its competitive edge in the dynamic medical technology field. However, BDX also faces significant risks including economic factors, competitive pressures, healthcare industry changes, raw material costs, regulatory compliance, and litigation.

This 10-K filing for Becton Dickinson & Co. (BDX) for the period ending September 29, 1999, provides a snapshot of the company's financial health and operational status at the close of the fiscal year. Investors should note that while specific financial figures are not detailed in the provided excerpt, the filing's existence indicates a mature company adhering to SEC reporting standards. Key areas for investors to scrutinize within the full report would typically include detailed financial statements (income statement, balance sheet, cash flow), management's discussion and analysis of financial condition and results of operations, and any significant risk factors or legal proceedings. Given the filing date of December 10, 1999, the report reflects the company's performance heading into the new millennium, an era of significant technological and global economic shifts.

Becton Dickinson & Co. (BDX) filed its 10-K annual report for the fiscal year ended September 29, 1998. This filing provides a comprehensive overview of the company's financial performance, business operations, and strategic direction. As a leading medical technology company, BDX's performance in this period is critical for understanding its trajectory and market position. Investors should pay close attention to revenue growth, profitability, and any significant investments or acquisitions that may shape its future. The report highlights BDX's commitment to innovation and expanding its product portfolio across its key business segments. The company's focus on healthcare needs, such as infection control and diagnostics, positions it to benefit from demographic trends and increased healthcare spending. Understanding the company's strategy for organic growth and potential M&A activity will be key for assessing its long-term value creation potential.

This 10-K filing from BECTON DICKINSON & CO (BDX) for the fiscal year ending September 29, 1997, indicates a company operating within the healthcare sector. While the provided text is primarily a directory listing and does not contain detailed financial statements or management discussion, it signifies that BDX has completed its annual reporting requirements for the period. Investors would typically look for information on revenue growth, profitability, key business segments, any significant acquisitions or divestitures, and the company's strategic outlook in a full 10-K report. As this excerpt is limited, a comprehensive analysis of BDX's financial health and operational performance for fiscal year 1997 cannot be made. The filing date of December 16, 1997, suggests the report is being submitted shortly after the fiscal year-end, a standard practice. Investors should consult the full 10-K document, including the financial statements, management's discussion and analysis (MD&A), and risk factors, for a complete understanding of the company's performance and future prospects.

BECTON DICKINSON & CO (BDX) filed its 1995 Annual Report (10-K) on December 27, 1995, covering the period ending September 29, 1995. This filing provides a snapshot of the company's financial health and operational performance for the fiscal year. While specific financial figures and detailed operational discussions are not present in the provided snippet, the filing itself signifies BD's commitment to transparent reporting for its investors. Investors should look to the full 10-K document for crucial details on revenue, profitability, cash flows, balance sheet strength, and management's outlook. Key areas of focus for investors would typically include revenue growth across its various business segments, profitability margins, debt levels, and any significant capital expenditures or strategic initiatives undertaken during the year. The nature of BDX's business in medical technology and devices suggests a focus on innovation, regulatory compliance, and market penetration as drivers of performance.

Becton Dickinson & Co. (BDX) filed its 1994 10-K report for the period ending September 29, 1994. This filing provides a look into the company's financial performance and operational standing from that fiscal year. Investors seeking insights into BDX's historical performance should examine the detailed financial statements and management's discussion and analysis presented in the full report. While this specific filing extract is limited in detailed financial data, it serves as a record of BDX's compliance and reporting for the period. The full 10-K would contain crucial information regarding revenue, profitability, assets, liabilities, cash flows, and any significant business developments or risks faced by the company during that time. It's essential for investors to consult the complete document for a comprehensive understanding of Becton Dickinson's financial health and strategic direction in 1994.